생쥐의 실험대장염 모델에서 HMG-CoA 환원효소 억제제 Atorvastatin의 효과
Effect of Atorvastatin, a HMG-CoA Reductase Inhibitor, in Experimental Colitis in Mice
0
조회
0
다운로드
0
인용
0
참고문헌
초록
Abstract
Background : The statins, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, are approved for cholesterol reduction, and may also be beneficial in the treatment of inflammatory disease. In this study, atorvastatin was tested in experimental colitis, a disease model of inflammatory bowel disease. Methods : To induce colitis, dextran sodium sulfate (DSS) or trinitrobenzene sulfonic acid (TNBS) were administrated to C57BL/6 or BALB/c mice. Mice were monitored daily for loss of body weight and survival for indicated days. Colon length and histology were examined after sacrifice. Results : The administration of DSS induced marked colonic inflammation and shortening, and resulted in a loss of body weight. DSS-induced colitis was not affected by atorvastatin treatment, but in contrast, the administration of atorvastatin relieved TNBS-induced colitis with a resultant rapid recovery of weight loss and a reduction in colonic length shortening. Histologically, inflammatory cell infiltration in the colonic wall, mucosal ulceration and crypt disruption were also suppressed in atorvastatin treated mice. Conclusions : These results suggest that atorvastatin preserves intestinal integrity in colitis, probably via the modulation of Th cell-mediated immune response, in a manner independent of innate immunity.
참고문헌 (21)
- "Incidence and prevalence of ulcerativecolitis in the Songpa-Kangdong District, Seoul, Korea, 1986-1997.", 15, pp.1037~1042 (2000)
- "Epidemiology of inflammatorybowel disease in Asia.", 7, pp.260~270 (2001)
- "Crohn’s disease.", pp.62~69 (2002)
- "Ulcerative colitis.", 359, pp.331~340 (2002)
- "Animal models of inflammatory bowel disease-an overview"
- "Animal models of inflammatory boweldisease.", 37, pp.409~417 (2002)
- "Hapten-induced modelof murine inflammatory bowel disease: mucosa immune responsesand protection by tolerance.", 157, pp.2174~2185 (1996)
- "Apolipoprotein A-IV inhibitsexperimental colitis.", 114, pp.260~269 (2004)
- "Current perspectives on statins.", pp.207~213 (2000)
- "Effects of lowering averageof below-average cholesterol levels on the progression of carotidatherosclerosis results of the LIPID Atherosclerosis Substudy.", 97, pp.1784~1790 (1998)
- "Effects of statins on triglyceride metabolism.", 81, pp.32~35 (1998)
- "Lovastatin and phenylacetateinhibit the induction of nitric oxide synthase and cytokinesin rat primary astrocytes, microglia, and macrophages", 100, pp.2671~2679 (1997)
- "Statins as a newly recognizedtype of immunomodulator.", 6, pp.1399~1402 (2000)
- "The HMG-CoA reductaseinhibitor, atorvastatin, promotes a Th2 bias and reverses paralysisin central nervous system autoimmune disease.", 420, pp.78~84 (2002)
- "A novel method in the induction of reliable experimental acuteand chronic ulcerative colitis in mice", pp.694~702
- "Antibodies tointerleukin 12 abrogate established experimental colitis in mice,", 182, pp.1281~1290 (1995)
- "The immunology of mucosal modelsof inflammation.", 20, pp.495~549 (2002)
- "The 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor pravastatin reduces disease activityand inflammation in dextran-sulfate induced colitis.", 305, pp.78~85 (2003)
- "Statins selectivelyinhibit leukocyte function antigen-1 by binding to a novel regulatoryintegrin site.", 7, pp.687~692 (2001)
- "Inhibition of monocyte chemotacticprotein-1 synthesis by statins.", 80, pp.1095~1100 (2000)
- "inhibition of endogenous sterol synthesis prevents mitogeninducedhuman T cell proliferation", pp.2093~9